 SAN FRANCISCO and SUZHOU, China, July 07, 2021 GLOBE NEWSWIRE -- Adagene Inc. Adagene Nasdaq: ADAG, a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that its board of directors has authorized a share repurchase program under which, Adagene may repurchase up to US20 million of its ordinary shares in the form of American depositary shares, subject to the relevant rules under the Securities Exchange Act of 1934, as amended the Exchange Act, and the Companys insider trading policy. 